Albireo to Showcase New Data at AASLD The Liver Meeting®

Albireo to Showcase New Data at AASLD The Liver Meeting®

– Seven abstracts accepted, including one oral presentation highlighting long-term data demonstrating Bylvay® (odevixibat) durable efficacy in patients...

Related Keywords

United States , Germany , United Kingdom , Massachusetts , Washington , Belgium , Gothenburg , Vastra Gotalands Lan , Sweden , Italy , Boston , Austria , Spain , Northern Ireland , Craigavon , London , City Of , Scotland , Henkjanj Verkade , Colleen Alabiso , Lorenzo Dantiga , Lance Buckley , Richardj Thompson , Franciscoj Caballero Camino , Intrahepatic Cholestasis , Azienda Ospedaliera Papa Giovanni , Georg Friedrich Vogel , King College London , Albireo Pharma Inc , Department Of Paediatric Hepatology , University Of Innsbruck , Department Of Paediatrics , European Commission , Institute Of Liver , Nasdaq , Exchange Commission , Beatrix Children Hospital University Medical Centre Groningen , Astrazeneca , Healthcare Products Regulatory Agency , University Of Groningen , Access Program , American Association , Liver Diseases , Native Liver Survival , Progressive Familial Intrahepatic , Liver Studies , Pediatric Liver , Pooled Data , Beatrix Children , University Medical Centre Groningen , Poster Session , Long Term Efficacy , Progressive Familial Intrahepatic Cholestasis , College London , Odevixibat Treatment , Recurrent Episodic Cholestasis , Biallelic Mutations , Retrospective Case , Angelo Di Giorgio , Hospital Papa Giovanni , Odevixibat Therapy , Assistant Professor , Medical University , Innsbruck , Serum Bile Acid Levels , Pruritus Scores , Growth Over Time , Odevixibat Responders , Lorenzod Antiga , Paediatric Hepatology , Urinary Excretion , Bile Acids , Halts Liver Disease Progression , Obstructed Mice , Instituto De Investigaci , Sanitaria Biodonostia , San Sebasti , Basque Country , United Kingdom Medicines , Test Abnormalities , Soluble Vitamin , Open Label Extension , Private Securities Litigation Reform Act , Expanded Access Program , Annual Report , Nasdaq Albo , Albireo Pharma , Nc ,

© 2025 Vimarsana